Century Therapeutics (IPSC) reported second-quarter 2026 financial results, including a net loss of $34.6 million for the quarter ended June 30, 2026, compared with a net loss of $32.5 million in the same period of 2025.
The company said cash, cash equivalents and investments totaled $197.2 million as of June 30, 2026, with runway expected into the first quarter of 2029. Century also reported progress for CNTY-813 in type 1 diabetes and said CNTY-308 remains on track to enter the clinic in 2026.
- Collaboration revenue was $0 for the second quarter of 2026.
- R&D expenses were $19.6 million, down from $26.9 million a year earlier.
- G&A expenses were $5.8 million, down from $7.8 million a year earlier.
- Net loss per common share, basic and diluted, was $0.17.
- CNTY-813 IND submission remains on track for the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.
- CNTY-813 preclinical data are scheduled for oral presentations at EASD 2026 and Breakthrough T1D Clinical & Research Congress 2026.
$IPSC Insider Trading Activity
$IPSC insiders have traded $IPSC stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $IPSC stock by insiders over the last 6 months:
- GREGORY RUSSOTTI (See Remarks) has made 0 purchases and 4 sales selling 13,663 shares for an estimated $33,772.
- DOUGLAS CARR (SVP Finance & Operations) has made 0 purchases and 6 sales selling 9,732 shares for an estimated $23,958.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IPSC Hedge Fund Activity
We have seen 55 institutional investors add shares of $IPSC stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 17,754,430 shares (+inf%) to their portfolio in Q1 2026, for an estimated $40,125,011
- TCG CROSSOVER MANAGEMENT, LLC added 17,754,430 shares (+inf%) to their portfolio in Q1 2026, for an estimated $40,125,011
- VERSANT VENTURE MANAGEMENT, LLC added 12,166,109 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,495,406
- DEEP TRACK CAPITAL, LP added 9,487,745 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,442,303
- RTW INVESTMENTS, LP added 8,695,652 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,652,173
- COMMODORE CAPITAL LP added 8,695,652 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,652,173
- BLACKROCK, INC. added 6,567,346 shares (+430.8%) to their portfolio in Q2 2026, for an estimated $16,089,997
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
